Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)

NCT00899678 is registered in ClinicalTrials.gov with UCB Celltech as lead sponsor.

NCT NCT00899678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00899678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)
Lead sponsor
UCB Celltech
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2009
Completion date
July 31, 2012
Enrollment
99 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease